Executives from 7 drug companies appear before the Senate. Photo: Win McNamee/Getty Images

Drug companies have cheered the Trump administration's proposed crackdown on industry middlemen, but some hedged this morning when asked whether that plan would cause them to lower their prices.

The big picture: Pharmaceutical executives have stayed firmly on message even amid some tough questioning from the Senate Finance Committee.

What they're saying: Several lawmakers have taken a tough tone against the 7 executives testifying this morning about drug prices.

  • Sen. Ron Wyden (D-Ore.), for example, said AbbVie "protects the exclusivity of Humira like Gollum with his ring."
  • The pharmaceutical executives in attendance responded with many of the industry's standard arguments, including broadsides against pharmacy benefit managers and the drug rebate system PBMs rely on.

Between the lines: The Trump administration has proposed eliminating those PBM rebates in Medicare and Medicaid, saying that will also translate into lower sticker prices. Finance Chairman Chuck Grassley (R-Iowa) asked the executives whether they would, in fact, lower prices as a result of the rebate proposal.

  • AstraZeneca CEO Pascal Soriot and Merck CEO Ken Frazier both said their companies would lower drug prices if the rebate rule was applied to both the Medicare and commercial insurance markets. For now, it doesn't apply to commercial insurance.
  • Others said they similarly supported the rule, but hedged by saying costs would be lower for patients when they pick up the drug at the pharmacy — not necessarily that the health care system as a whole would be paying less.

Go deeper

Dion Rabouin, author of Markets
1 hour ago - Economy & Business

Investors are betting the future is priced in euros

Illustration: Aïda Amer/Axios

It's the euro's time now — at least that's how investors have been positioning recently.

What's happening: Speculators have raised their bets to the highest in nine years that the dollar will fall and increased bullish bets that the euro will rise to the highest level on record, Reuters reported citing data from the CFTC.

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios

  1. Global: Total confirmed cases as of 9 a.m. ET: 20,372,619 — Total deaths: 743,344— Total recoveries: 12,609,775Map.
  2. U.S.: Total confirmed cases as of 9 a.m. ET: 5,141,879 — Total deaths: 164,545 — Total recoveries: 1,714,960 — Total tests: 63,252,257Map.
  3. Business: U.S. already feeling effects of ending unemployment benefits — U.S. producer prices rose last month by the most since October 2018.
  4. Public health: America's flying blind on its coronavirus response.
Mike Allen, author of AM
3 hours ago - Politics & Policy

3 keys to Joe Biden picking Kamala Harris

Photo: Jeff Kowalsky/AFP via Getty Images

Three quick points about Joe Biden's historic selection of Sen. Kamala (pronounced COMMA-luh) Harris of California as his running mate — and clues they give us to how Biden would govern:

  1. She was always at the top of his list. As I look back through my text threads with top Dems over the past five months, she was always assumed to be the most likely pick.